ATYR PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.79 USD | -0.56% |
|
-13.53% | +26.95% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +26.95% | 124M | - | ||
| +54.05% | 63.85B | B- | ||
| -2.02% | 41.83B | B | ||
| +40.01% | 40.47B | A | ||
| -10.22% | 27.17B | C | ||
| +13.42% | 26.52B | B- | ||
| -21.60% | 18.69B | B | ||
| +2.89% | 12.73B | B+ | ||
| +22.40% | 12.11B | B+ | ||
| +27.49% | 12.07B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LIFE Stock
- Ratings aTyr Pharma, Inc.
